Lupin Upbeat On Biosimilar Etanercept After Q3 Profit Plunge

 
• By Penelope MacRae
Jigsaw
LUPIN REPORTED A WEAK QUARTER BUT IS UPBEAT ABOUT ITS BIOSIMILARS PORTFOLIO

More from Earnings

More from Business